Get the Stockscreener App
1.31
0.00%
+0.00
Clearside Biomedical Inc stock is currently priced at $1.31, with a 24-hour trading volume of 209.16K.
It has seen a +0.00% increased in the last 24 hours and a +3.97% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.32 pivot point. If it approaches the $1.28 support level, significant changes may occur.
Previous Close:
$1.31
Open:
$1.3
24h Volume:
209.16K
Market Cap:
$97.90M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-2.2203
EPS:
-0.59
Net Cash Flow:
$-19.91M
1W Performance:
+4.80%
1M Performance:
+3.97%
6M Performance:
+37.42%
1Y Performance:
+25.96%
1D Range:
$1.30
$1.34
52W Range:
$0.6501
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678 270 3631
Address
900 North Point Parkway, Suite 200, Alpharetta, GA
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-21 | Resumed | Wedbush | Outperform |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| May-13-20 | Initiated | ROTH Capital | Buy |
| Aug-09-19 | Downgrade | Needham | Buy → Hold |
| Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-05-18 | Downgrade | Stifel | Buy → Hold |
| Mar-06-18 | Reiterated | Needham | Buy |
| May-25-17 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-17 | Initiated | JP Morgan | Overweight |
| Nov-10-16 | Reiterated | Needham | Buy |
| Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Clearside Biomedical And 3 Other Penny Stocks Insiders Are Buying - Clearside Biomedical (NASDAQ:CLSD) - Benzinga
Benzinga
Brokers Set Expectations for Clearside Biomedical, Inc.'s FY2024 Earnings (NASDAQ:CLSD) - Defense World
Defense World
Brokers Set Expectations for Clearside Biomedical, Inc.'s FY2024 Earnings (NASDAQ:CLSD) - Defense World
Defense World
Clearside Biomedical director buys $10.2k in company stock - Investing.com
Investing.com
FY2024 EPS Estimates for Clearside Biomedical, Inc. Cut by Analyst (NASDAQ:CLSD) - MarketBeat
MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Rating Reiterated by Needham & Company LLC - Defense World
Defense World
Clearside Biomedical Inc Stock (CLSD) Financials Data
Clearside Biomedical Inc (CLSD) Revenue 2024
CLSD reported a revenue (TTM) of $8.23 million for the quarter ending December 31, 2023, a +519.89% rise year-over-year.
Clearside Biomedical Inc (CLSD) Net Income 2024
CLSD net income (TTM) was -$32.48 million for the quarter ending December 31, 2023, a +1.40% increase year-over-year.
Clearside Biomedical Inc (CLSD) Cash Flow 2024
CLSD recorded a free cash flow (TTM) of -$19.91 million for the quarter ending December 31, 2023, a -46.29% decrease year-over-year.
Clearside Biomedical Inc (CLSD) Earnings per Share 2024
CLSD earnings per share (TTM) was -$0.53 for the quarter ending December 31, 2023, a +3.64% growth year-over-year.
Clearside Biomedical Inc Stock (CLSD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | Director |
Apr 18 '24 |
Buy |
1.30 |
93,290 |
121,277 |
100,000 |
| Gibney Anthony S | Director |
Apr 17 '24 |
Buy |
1.25 |
6,710 |
8,388 |
6,710 |
| Chong Ngai Hang Victor | CHIEF MEDICAL OFFICER |
Mar 20 '24 |
Buy |
1.60 |
30,000 |
48,000 |
30,000 |
| WHITMORE BRADFORD T | 10% Owner |
Feb 07 '24 |
Buy |
1.35 |
444,444 |
599,999 |
4,495,034 |
| LASEZKAY GEORGE M | CEO |
Jan 19 '24 |
Sale |
1.27 |
18,000 |
22,860 |
466,577 |
| Deignan Charles A. | Chief Financial Officer |
Jan 19 '24 |
Sale |
1.28 |
12,900 |
16,512 |
384,662 |
| WHITMORE BRADFORD T | 10% Owner |
Nov 01 '23 |
Buy |
0.74 |
64,366 |
47,901 |
4,050,590 |
| WHITMORE BRADFORD T | 10% Owner |
Oct 31 '23 |
Buy |
0.73 |
70,812 |
51,537 |
3,986,224 |
| WHITMORE BRADFORD T | 10% Owner |
Oct 30 '23 |
Buy |
0.69 |
600 |
411 |
3,915,412 |
| Hutson Nancy J | Director |
Oct 03 '23 |
Buy |
0.86 |
10,000 |
8,600 |
93,000 |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
0.77%
1.20%
Cap:
|
Volume (24h):